Cambridge, UK; 10th September 2020. 

Atlantic Healthcare plc (Atlantic Healthcare) is delighted to announce that David Bennett has strengthened the senior leadership team as Chief Operations Officer. This significant appointment occurs as the company prepares to complete its numerous late stage clinical programmes and move towards global commercialization.

David started his pharmaceutical career as a manufacturing engineer for 3M Pharmaceuticals, before moving into market research and European strategic branding. As General Manager of MEDA Pharmaceuticals UK and as President & Managing Director of Galen (the pharmaceutical division of Almac Group), David established a track record in senior management roles across pharmaceutical operations, team leadership and commercialization of products, including therapeutics for gastrointestinal diseases, across Europe and the U.S.

In David’s most recent position, as Vice President, Syneos Health, he worked with multiple international pharmaceutical and life science companies, assessing and designing their organizational needs to successfully launch and commercialize products across Europe.

David Bennett, Chief Operations Officer said

I can see the real potential in developing Atlantic Healthcare as a different type of transatlantic pharmaceutical company.  I’m excited about the vision.

 Atlantic Healthcare is a ‘late stage development company’ supported by an experienced commercial team with deep roots in the pharmaceutical industry.

 There is an exciting opportunity to position the company’s products to deliver a step change in treatment and a real difference for patients, in the target gastrointestinal indications.”

 An approach of re-examining ‘where’ the opportunity lies and ‘how’ to take a particular product to market underpins the strategic commercial focus of Atlantic Healthcare. By completing product development and building the infrastructure to commercialize, the company is working in clinical areas where much-needed novel solutions are urgently required.

Toby Wilson Waterworth, CEO of Atlantic Healthcare said: “We are delighted to welcome David who brings great commercial perspective to our senior leadership team. His vision and expertise are completely aligned with ours to establish Atlantic Healthcare as a profitable transatlantic pharmaceutical company. He joins us as we start to structure our plans for product commercialization.”

About Atlantic Healthcare

David Bennett on LinkedIn:

Atlantic Healthcare plc ( is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.

 The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders.

Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products itself in the U.S. and Europe and through partnerships and licensing with established pharmaceutical companies in the rest of the world.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.

For more information about Atlantic Healthcare, investment, alicaforsen or renzapride, please contact:

Adam Michael (Head of Communications)

+44 1799 512 055

+44 777 588 1813


Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal

+44 20 3709 5700